ATE445402T1 - Neue verwendung von pde5-hemmern - Google Patents
Neue verwendung von pde5-hemmernInfo
- Publication number
- ATE445402T1 ATE445402T1 AT05716901T AT05716901T ATE445402T1 AT E445402 T1 ATE445402 T1 AT E445402T1 AT 05716901 T AT05716901 T AT 05716901T AT 05716901 T AT05716901 T AT 05716901T AT E445402 T1 ATE445402 T1 AT E445402T1
- Authority
- AT
- Austria
- Prior art keywords
- pde5 inhibitors
- new use
- pde5
- inhibitors
- new
- Prior art date
Links
- 229940123333 Phosphodiesterase 5 inhibitor Drugs 0.000 title abstract 2
- 239000002590 phosphodiesterase V inhibitor Substances 0.000 title abstract 2
- 239000003814 drug Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Psychology (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Vascular Medicine (AREA)
- Reproductive Health (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP04100909 | 2004-03-05 | ||
| PCT/EP2005/050958 WO2005089766A1 (en) | 2004-03-05 | 2005-03-03 | Novel use for pde5 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE445402T1 true ATE445402T1 (de) | 2009-10-15 |
Family
ID=34928893
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT05716901T ATE445402T1 (de) | 2004-03-05 | 2005-03-03 | Neue verwendung von pde5-hemmern |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US7666872B2 (de) |
| EP (1) | EP1740183B8 (de) |
| JP (1) | JP4838792B2 (de) |
| AT (1) | ATE445402T1 (de) |
| AU (1) | AU2005224043B2 (de) |
| CA (1) | CA2557792C (de) |
| DE (1) | DE602005017135D1 (de) |
| ES (1) | ES2334682T3 (de) |
| WO (1) | WO2005089766A1 (de) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8841300B2 (en) * | 2006-10-02 | 2014-09-23 | Jerry M. Held | Treatment for Parkinson's disease—combination high dose serotonergic synaptic reuptake inhibitor with phosphodiesterase inhibitor |
| CN101547922B (zh) | 2006-10-04 | 2012-06-20 | 辉瑞产品公司 | 作为钙受体拮抗剂的吡啶并[4,3-d]嘧啶-4(3H)-酮衍生物 |
| JP2010527928A (ja) * | 2007-05-18 | 2010-08-19 | ヴィヴァス・インコーポレイテッド | ホスホジエステラーゼ−５阻害剤を含む新規の組み合わせおよびそれらの使用 |
| KR101002490B1 (ko) * | 2007-06-09 | 2010-12-17 | 동아제약주식회사 | 유데나필을 유효성분으로 함유하는 만성 심부전증 치료용약학적 조성물 |
| AU2012201640B2 (en) * | 2007-06-13 | 2014-09-04 | Vivus, Inc. | Treatment of pulmonary hypertension with carbonic anhydrase inhibitors in combination with a sympathomimetic amine |
| AU2014213552B2 (en) * | 2007-06-13 | 2016-11-24 | Vivus, Inc. | Treatment of pulmonary hypertension with carbonic anhydrase inhibitors in combination with a sympathomimetic amine |
| US8071557B2 (en) | 2007-06-13 | 2011-12-06 | Vivus, Inc. | Treatment of pulmonary hypertension with carbonic anhydrase inhibitors |
| JP5615805B2 (ja) * | 2008-04-29 | 2014-10-29 | ファーネクストＰｈａｒｎｅｘｔ | 細胞ストレス応答の調節を通したアルツハイマー病および関連障害の処置のための新たな治療アプローチ |
| EA018721B1 (ru) * | 2008-08-25 | 2013-10-30 | Айрм Ллк | Модуляторы сигнального пути hedgehog |
| US8962770B2 (en) * | 2009-12-30 | 2015-02-24 | Sabic Global Technologies B.V. | Blends of isosorbide-based copolycarbonate, method of making, and articles formed therefrom |
| US8888802B2 (en) * | 2010-12-21 | 2014-11-18 | Alcon Research, Ltd. | Vitrectomy probe with adjustable cutter port size |
| EP2535049A1 (de) * | 2011-06-17 | 2012-12-19 | Proyecto de Biomedicina Cima, S.L. | Tadalafil zur Behandlung von Demenz |
| AT512084A1 (de) | 2011-10-20 | 2013-05-15 | Univ Wien Tech | Diazabicyclo- und diazaspiro-alkanderivate als phosphodiesterase-5 inhibitoren |
| RU2497203C2 (ru) * | 2012-02-13 | 2013-10-27 | Государственное бюджетное образовательное учреждение высшего профессионального образования "Курский государственный медицинский университет" Министерства здравоохранения и социального развития Российской Федерации | Способ фармакологической коррекции ишемии скелетной мышцы силденафилом, в том числе при l-name-индуцированном дефиците оксида азота |
| DK2961741T3 (en) * | 2013-03-01 | 2017-07-03 | Fund Para La Investig Medica Aplicada | Novel compounds as dual inhibitors of phosphodiesterases and histone deacetylases |
| IT201700085714A1 (it) * | 2017-07-26 | 2019-01-26 | Luigi Maiuri | Approccio terapeutico per il trattamento e/o prevenzione di condizioni di sensibilità al glutine. |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5698560A (en) | 1995-03-01 | 1997-12-16 | Kyowa Hakko Kogyo Co., Ltd. | Imidazoquinazoline derivatives |
| US6018046A (en) * | 1996-05-31 | 2000-01-25 | Mochida Pharmaceutical Co., Ltd. | Pyridocarbazole derivatives having cGMP-PDE inhibitory activity |
| WO1998038168A1 (en) * | 1997-02-27 | 1998-09-03 | Tanabe Seiyaku Co., Ltd. | Isoquinolinone derivatives, process for preparing the same, and their use as phosphodiesterase inhibitors |
| JPH10298164A (ja) * | 1997-02-27 | 1998-11-10 | Tanabe Seiyaku Co Ltd | イソキノリノン誘導体、その製法及びその合成中間体 |
| CA2387353A1 (en) * | 1999-10-11 | 2001-04-19 | Charlotte Moira Norfor Allerton | Pharmaceutically active compounds |
| IL139073A0 (en) * | 1999-10-21 | 2001-11-25 | Pfizer | Treatment of neuropathy |
| ES2278927T3 (es) * | 2001-05-09 | 2007-08-16 | Bayer Healthcare Ag | Nuevo uso de imidazotriazinonas de 2-(2-etoxi-5-(4-metil-piperazin-1-sulfonil)-fenil)-5-metil-7-propil-3h-imidazo(5,1-f)(1,2,4)triazin-4-ona. |
| GB0129274D0 (en) * | 2001-12-06 | 2002-01-23 | Pfizer Ltd | Novel kit |
| WO2003051346A2 (en) | 2001-12-17 | 2003-06-26 | Altana Pharma Ag | Use of selective pde5 inhibitors for treating partial and global respiratory failure |
-
2005
- 2005-03-03 AT AT05716901T patent/ATE445402T1/de not_active IP Right Cessation
- 2005-03-03 WO PCT/EP2005/050958 patent/WO2005089766A1/en active Search and Examination
- 2005-03-03 CA CA2557792A patent/CA2557792C/en not_active Expired - Fee Related
- 2005-03-03 US US10/590,992 patent/US7666872B2/en not_active Expired - Fee Related
- 2005-03-03 DE DE602005017135T patent/DE602005017135D1/de not_active Expired - Lifetime
- 2005-03-03 AU AU2005224043A patent/AU2005224043B2/en not_active Ceased
- 2005-03-03 ES ES05716901T patent/ES2334682T3/es not_active Expired - Lifetime
- 2005-03-03 JP JP2007501295A patent/JP4838792B2/ja not_active Expired - Fee Related
- 2005-03-03 EP EP05716901A patent/EP1740183B8/de not_active Expired - Lifetime
-
2010
- 2010-01-04 US US12/654,787 patent/US8278300B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP1740183B8 (de) | 2009-11-25 |
| ES2334682T3 (es) | 2010-03-15 |
| US20100179152A1 (en) | 2010-07-15 |
| CA2557792C (en) | 2012-12-18 |
| JP2007526285A (ja) | 2007-09-13 |
| US7666872B2 (en) | 2010-02-23 |
| EP1740183B1 (de) | 2009-10-14 |
| EP1740183A1 (de) | 2007-01-10 |
| DE602005017135D1 (de) | 2009-11-26 |
| CA2557792A1 (en) | 2005-09-29 |
| AU2005224043B2 (en) | 2010-06-24 |
| US20070185114A1 (en) | 2007-08-09 |
| US8278300B2 (en) | 2012-10-02 |
| WO2005089766A1 (en) | 2005-09-29 |
| AU2005224043A1 (en) | 2005-09-29 |
| JP4838792B2 (ja) | 2011-12-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE445402T1 (de) | Neue verwendung von pde5-hemmern | |
| NO20071127L (no) | Triazoloftalaziner | |
| ATE477249T1 (de) | Heteroarylbenzamidderivate zur verwendung als glk-aktivatoren bei der behandlung von diabetes | |
| EA200870409A1 (ru) | Антагонисты киназы pi3 | |
| ATE461217T1 (de) | Glp-1-verbindungen | |
| NO20081636L (no) | FAP - inhibitorer | |
| UY3493Q (es) | Esponja | |
| HN2005000477A (es) | Compuestos de aminoheteroarilo sustituidos con piraol como inhibidores de proteina quinasa | |
| ATE400567T1 (de) | Kinaseinhibitoren | |
| CY1109741T1 (el) | Sns-595 και μεθοδοι χρησης αυτου | |
| DE602005017302D1 (de) | Synchronisierung von parametrischer raumtonkodierung mit extern bereitgestelltem downmix | |
| EA201270630A1 (ru) | Гетероциклические сетр ингибиторы | |
| EA200601568A1 (ru) | Новые гидрокси-8-гетероарилфенантридины и их применение в качестве ингибиторов pde4 | |
| DE502004011575D1 (de) | Verwendung von Dioldimerfettsäureestern | |
| EA200700702A1 (ru) | Аналоги локсапина и способы их применения | |
| ATE417842T1 (de) | Verwendung von trisubstituierten benzopyranonen | |
| ATE486878T1 (de) | Benzothienopyridine zur verwendung als inhibitoren von eg5-kinesin | |
| ATE388941T1 (de) | Neue pyrimidin-4,6-dicarbons urediamide zur selektiven inhibierung von kollagenasen | |
| ATE466819T1 (de) | Verwendung von nitratsalzen zur unterdrückung störender gerüche | |
| DE602006012938D1 (de) | Neue 6-pyridylphenanthridine | |
| DE602005022920D1 (de) | Verbesserungen bei der verwendung von mehrfachkommunikationssystemen | |
| DE602004011946D1 (de) | Alkalisalze von protonenpumpen-hemmern | |
| CY1111328T1 (el) | Χαρακτηρισμος: αξομαδολη για τη θεραπεια πονου σε αρθριτιδα | |
| EP1931370A4 (de) | Verwendung von des-aspartat-angiotensin i | |
| ATE550351T1 (de) | Vegf-d-mutanten und ihre verwendung |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |